Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate by Maire, Cecile L et al.
	
	
 
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation 
rate  
	
	
Mark M. Stevens1,2,*, Cecile L. Maire6,*, Nigel Chou1,3,*, Mark A. Murakami6, *, David Knoff 6, Yuki Kikuchi1,7, 
Robert J. Kimmerling1,3, Huiyun Liu6, Samer Haidar6, Nicholas L. Calistri1, Nathan Cermak1,4, Selim Olcum1, 
Nicolas Cordero6, Ahmed Idbaih8,9,10,11,12, Patrick Y. Wen6, David M. Weinstock 6,13,†, Keith L. Ligon6,14,15,†, Scott 
R. Manalis1,3,5,† 
 
AFFILIATIONS: 1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 
Cambridge, MA, 2Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, 3Department 
of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 4Department of 
Computational and Systems Biology, Massachusetts Institute of Technology, Cambridge, MA, 5Department of 
Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 6Department of Medical 
Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 7Hitachi High-Technologies 
Corporation, Ibaraki-ken, Japan, 8AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, 
Paris, France, 9Sorbonne Universités, Paris, France, 10Inserm, Paris, France, 11CNRS, Paris, France, 12Institut du 
Cerveau et de la Moelle epiniere, Paris, France, 13Broad Institute, Cambridge, MA, 14Department of Pathology, 
Children’s Hospital Boston, Boston, MA, 15Department of Pathology, Brigham and Women’s Hospital, Boston, 
MA 
	
	
* these authors contributed equally to this work	
† corresponding authors  
email: (srm@mit.edu, davidm_weinstock@dfci.harvard.edu, keith_ligon@dfci.harvard.edu) 
  
Assays that can determine the response of tumor cells to cancer therapeutics could greatly aid the selection 
of drug regimens for individual patients. However, no functional assays are currently implemented 
clinically, and predictive genetic biomarkers are available for only a small fraction of cancer therapies. 
Here we demonstrate that the single-cell mass accumulation rate (MAR), profiled over many hours with a 
suspended microchannel resonator, accurately defines the drug sensitivity or resistance of glioblastoma 
multiforme (GBM) and B-cell acute lymphocytic leukemia (B-ALL) cells. MAR reveals heterogeneity in 
drug sensitivity not only between different tumors but also within individual tumors and tumor-derived cell 
lines. MAR measurement predicts drug response using samples as small as 25 µL of peripheral blood while 
maintaining cell viability and compatibility with downstream characterization. MAR measurement is a 
promising approach for directly assaying single-cell therapeutic responses and for identifying cellular 
subpopulations with phenotypic resistance within heterogeneous tumors.		
	
The choice of drug regimens for individual cancer patients has historically been based on treatment responses 
observed in large studies across heterogeneous populations. The shortcomings of this approach have motivated a 
broad effort to personalize treatment decisions for each patient based on the presence or absence of genetic, 
epigenetic or other biomarkers within an individual tumor 1, 2. Although population-based studies have been 
successful in some instances (e.g., in lung cancers with mutations of EGFR or rearrangements involving ALK), the 
vast majority of cancer therapeutics have no known markers for susceptibility or resistance 3. Even when marker-
based predictions can be made, they do not guarantee patient response, as many are the result of correlations from 
population-based studies 4, 5.	
 
The second major shortcoming of nearly all available biomarkers is that they are derived from analyses of bulk 
tumor populations, and thus do not predict the emergence of resistant subpopulations. More sensitive approaches 
of genetic characterization, like single-cell sequencing, are becoming increasingly common as research platforms 
but are not yet amenable to a clinical setting 6, 7. These approaches also suffer from the same shortcoming as bulk 
assays, i.e., the lack of predictive genetic or transcriptional markers. 
 
In contrast to most biomarkers, functional assays can provide phenotype-driven predictors of therapeutic response 
that represent the integrated output of multi-parameter datasets, including genetic, epigenetic, environmental and 
other variables that determine response. Detection of clinical functional response in a patient following treatment 
initiation is currently measured indirectly by imaging (e.g. bulk tumor volume) or more rarely by direct 
measurement of tumor burden (e.g. peripheral blast counts). However, these assessments are delayed in time 
(ranging from days to months) and clinical indicators are only useful for making post-hoc treatment decisions. In 
the ideal scenario, therapeutic functional assays would be used to guide selection of treatment that would induce 
response and thereby avoid problematic side effects from inefficacious therapies. 
 
Although functional assays are essential clinical tools in assessing the antibiotic susceptibility of microbes, no 
such approaches have been widely adopted for patients with cancer 8, 9. Existing platforms to measure cancer cell 
growth, such as ATP-based assays (CellTiter-Glo), require extended time in culture and a large number of tumor 
cells 10. This precludes their use for the large majority of patients, who have limited amounts of cancer tissue 
available. Furthermore, these bulk approaches are ill-suited for characterizing therapeutic susceptibility of 
subpopulations that exist within heterogeneous tumors 10. 
 
An ideal functional assay for predicting therapeutic response in patients with cancer would have the following 
characteristics: 1) accurately measure responses to both single drugs and drugs in combination, 2) require 
minimal sample input, 3) avoid artifacts that result from long-term, in vitro culture, 4) quantify therapeutic 
response at the single-cell level, 5) return results within a timeframe conducive to therapeutic decision making, 
and 6) maintain cell viability to allow for downstream functional and molecular interrogations.  
 
	
We have developed an approach for functionally assessing the therapeutic sensitivity of single cancer cells by 
weighing each cell repeatedly over a 15-minute period in a suspended microchannel resonator (SMR) (Fig. 1a) 
11-13, either in the presence or absence of cancer therapeutics. Resonator-based approaches have been used to 
measure an array of cellular physical properties14, and, in one preliminary study, response to therapeutics 15. 
Following the incubation of tumor cells with drug, the SMR can detect changes in the growth of single cells to 
predict therapeutic response without the need for extended culture. To validate this approach, we applied the 
SMR to traditional cancer cell lines, patient-derived cell lines (PDCLs) and primary leukemia cells. 
	
RESULTS 
Mass accumulation rate (MAR) measurement 
The SMR is a cantilever-based microfluidic mass sensor that measures the buoyant mass (referred to hereafter 
simply as mass) of live single cells with a resolution near 50 fg, which is highly precise given that the average 
buoyant mass of a hematopoietic cell is ~75 pg 11. Cells are measured in suspension while under culture 
conditions, with controlled media temperature and CO2 concentration to maintain cell viability and growth
13. A 
series of mass measurements is made on an individual cell every ~30 seconds for ~15 minutes, allowing for 
determination of the mass accumulation rate (MAR), which is defined as the change in mass over time (Fig. 
1a)12. In addition to the MAR we also use the absolute single-cell mass as a biomarker, which is determined for 
each cell during the MAR measurement. By performing the MAR measurement on multiple cells from the same 
population, the SMR reveals heterogeneity in mass and MAR across the population, rather than an average of 
the tumor bulk. The degree to which mass and MAR behave as independent biomarkers varies depending on 
conditions and cell type. Although linear discriminate analysis (LDA) maximizes the predictive capability of 
these two biomarkers, we have used a simplified metric of MAR normalized by mass for most of the studies in 
this paper. 
 
 
Single-cell MARs reveal tumor growth heterogeneity  
In order to better characterize the platform’s performance, we applied this method to two cancer cell types known 
to be viable and proliferate in suspended cell culture: GBM and acute leukemias. First, we analyzed a fast growing 
GBM-PDCL (BT145) which grows as free-floating “stem-like” cells and tumorspheres, as well as primary 
leukemia cells isolated directly from mice with genetically-engineered, BCR-ABL-expressing acute lymphoblastic 
leukemia (BCR-ABL ALL). Consistent with our previous findings 12, the SMR was able to quantify MAR of 
single cells over ~15 minutes intervals with high signal-to-noise ratios in both tumor types (Fig. 1b). During this 
time, the cells acquired less than a few picograms of biomass. This is equivalent to an increase in cell diameter on 
the order of only 10 nm.  
 
To determine whether cell proliferation potential could be maintained after passage through the SMR, single 
BT145 GBM cells were isolated after MAR measurement and then assayed for their ability to form tumorspheres. 
Overall, 14 (35.9%) of 39 single cells formed tumorspheres compared to 217 (45.2%) of 480 single cells isolated 
directly from a bulk culture (p=0.26; Supplementary Fig. 1). Thus, MAR measurement had no statistically 
significant effect on viability or stem-like cell phenotype. 
 
The heterogeneity of single-cell growth across cell lines or patient models has not been well characterized. In 
BT145 cells, MAR measurements enabled delineation of different growth populations, identifying cells of both 
large and small mass with positive, zero and negative MAR (Fig. 1b). GBM tumors are known to harbor an 
exceptionally diverse admixture of growing, senescent, quiescent, and dying cells 16, 17. Examination of BT145 by 
immunohistochemistry also supported maintenance of these heterogeneous properties (Supplementary Fig. 2). 
Thus, heterogeneity of MAR and mass within this line seems to parallel the known growth heterogeneity and 
morphological diversity of cells seen in primary GBMs. In contrast, almost all primary BCR-ABL ALL cells had 
positive MARs that monotonically increased with cell mass (Fig. 1b). 
 
To determine the range of growth diversity that might exist across patients in a single tumor type, we measured 
MARs of single cells from seven different GBM-PDCLs with diverse genotypes (Supplementary Table 1) over 
three successive passages (Supplementary Fig. 3)18. MAR measurements demonstrated significant inter- and intra-
PDCL heterogeneity across the seven PDCLs with single-cell diversity in both MAR and mass. These findings 
were in stark contrast with the homogeneity of MARs across conventional hematopoietic cell lines, such as the 
L1210 leukemia cell line and the murine lymphoblastoid BaF3 cell line engineered to express BCR-ABL (BaF3 
BCR-ABL) (Fig. 1c). Such homogeneity did not appear related to the advanced age and passage of these lines as 
the conventional GBM cell line U87 exhibited significant MAR heterogeneity. Some lines like BT159 and BT145 
had more homogenous patterns of cell proliferation, whereas BT320 and BT179 exhibited the most heterogeneous 
phenotypes, findings supported by immunohistochemistry analysis (Supplementary Fig. 2). The extent of growth 
heterogeneity within individual GBM-PDCLs was maintained across consecutive passages (Supplementary Fig 
3), suggesting that intra-tumoral diversity in growth is an inherent property of GBM PDCLs even during in vitro 
propagation. 
 
MAR predicts cell line sensitivity to targeted therapy 
To test the ability of MAR measurements to predict drug susceptibility in an established cell line, we utilized BaF3 
cells engineered to express either wild-type BCR-ABL or the imatinib-resistant mutant BCR-ABL T315I19, 20. 
Treatment of BaF3-BCR-ABL cells with the tyrosine kinase inhibitor (TKI) imatinib at a therapeutically 
achievable concentration of 1 µM for only 2-4 hrs significantly decreased MAR without altering the distribution of 
mass (Fig. 2). With longer durations of exposure to imatinib, the reduction in MAR became more pronounced (Fig. 
2b) and cell mass was reduced (Fig. 2c). When the same conditions were applied to BaF3-BCR-ABL T315I cells, 
no significant change was observed in MAR or mass distributions (Fig. 2). However, exposure of these cells to the 
third-generation TKI ponatinib, which retains activity against BCR-ABL T315I, recapitulated the same reduction 
in MAR observed upon imatinib treatment of BaF3-BCR-ABL cells (Fig. 2b)20. Thus, MAR can distinguish 
therapeutic susceptibility from resistance within single BaF3 cells after only a few hours of drug exposure. 
 Next, we tested the ability of MAR measurements to predict therapeutic susceptibility when applied to GBM- 
PDCLs which have heterogeneous and complex MAR profiles and include cycling (non-G0) as well as non- 
cycling cells (G0) (Figure 1, Supplementary Fig. 2)16, 17. GBM is highly resistant to most therapeutics, but we 
previously reported sensitivity of some GBM-PDCLs to targeted MDM2 inhibition 21. In bulk tumors and cultures, 
MDM2 inhibitors are known to induce response in cells which have MDM2 amplification and wild-type TP53, 
whereas cells with mutant or deleted TP53 are completely resistant to MDM2 inhibitors. However, cells with wild-
type MDM2 and wild-type TP53 have unpredictable sensitivity to MDM2 inhibitors in GBM and other tumor cell 
types 22. We utilized the MDM2 inhibitor RG7112, a compound being evaluated in clinical trials, to test how 
single-cell MAR response of five GBM-PDCLs across this spectrum of MDM2 and TP53 mutational backgrounds 
might empirically correspond with genetics and CTG bulk sensitivity measures 23. BT484 and 3731 cells, which 
are MDM2 amplified and TP53 wild-type, had primarily negative MARs after incubation with 1 µM RG7112 for 
13-24 hrs (Fig. 3, Supplementary Fig. 4). With increasing time, the number of cells with negative MAR further 
increased until 25-36 hrs, when >80% of cells were losing mass in both PDCLs (Fig. 3, Supplementary Fig. 4). In 
comparison, BT333 cells, which are MDM2 wild-type and TP53 mutant, had no significant change in MAR 
compared to a DMSO-treated control over 36 hrs of RG7112 exposure (Fig. 3, Supplementary Fig. 4). 
 
Contrasting the predictable sensitivity and resistance of the aforementioned lines, the response of MDM2- 
wildtype, TP53-wildtype cells is not clearly correlated to MDM2/TP53 genotype. For example, targeted and whole 
exome sequencing of BT159, which are MDM2 and TP53 wild-type, identified no mutations or copy number 
alterations in TP53, TP63, TP73, CDKN2A, MDM4, mitochondrial apoptosis mediators or other p53- related genes 
that could mediate MDM2 inhibitor resistance. However, BT159 exhibited no evidence of single- cell response by 
36 hrs using MAR measurements, similar to the complete resistance exhibited by TP53-mutant BT333 cells (Fig. 
3, Supplementary Fig. 4). MAR measurements for all lines was consistent with the response in viability as 
measured by CTG after 72 hours of RG7112 exposure (Supplementary Fig. 5). 
 MAR predicts primary cell sensitivity to targeted therapy 
Next, we asked whether MAR measurements could effectively predict therapeutic response in primary tumor cells 
measured immediately after isolation from the in vivo setting. We harvested transgenic murine ALLs that express 
BCR-ABL or BCR-ABL T315I from the spleen of mice and flow-sorted to purify leukemia cells (Supplementary 
Fig. 6) 24. Single-cell MAR data was collected after 10-20 hrs of treatment with 1 µM imatinib or 100 nM 
ponatinib. Across three independent biological replicates, we observed a significant reduction in average MAR for 
leukemias expressing BCR-ABL upon treatment with imatinib or ponatinib, as well as for leukemias expressing 
BCR-ABL T315I upon treatment with ponatinib (Fig. 4a). By contrast, imatinib had no effect on leukemias 
expressing BCR-ABL T315I (Fig. 4a). We confirmed that BCR-ABL T315I leukemias are truly resistant to the 
imatinib analog nilotinib in situ by treatment of mice engrafted with these leukemias (Supplementary Fig. 7). In 
contrast to the marked effect of imatinib on MAR of wild-type BCR-ABL leukemia cells, exposure to imatinib in 
vitro for 24 hrs had no effect on the viability of leukemias expressing wild-type BCR-ABL in bulk culture, as 
determined by flow cytometry for Annexin V and DAPI (Supplementary Fig. 6a). Thus, the effect on MAR 
precedes these more standard metrics of drug response.  
 
In order to gauge how robustly MAR measurements can predict primary ALL single-cell drug sensitivity, we 
generated a receiver-operating characteristic (ROC) after performing linear discriminate analysis (LDA) on each 
replicate’s dataset. So far we have used the single metric of MAR per mass, however we also considered MAR and 
mass as independently variable biomarkers. LDA projects the populations of the two-dimensional MAR versus 
mass data onto a single axis that provides the best ability to distinguish two populations, and then defines the ideal 
threshold for this classification (Fig. 4b). Subsequent ROC curve analysis is performed and its area under the curve 
(AUC) is a metric of the ability to properly identify a single cell’s classification as sensitive or resistant to therapy 
25. A random classifier has an AUC equal to 0.5, and a perfect classifier has an AUC of 1. The average AUC of 
non-selective conditions (DMSO-treated compared to imatinib-treated T315I-mutant leukemia) was 0.57, 
consistent with the expectation that resistant cells are indistinguishable from untreated cells (Fig. 4a,c). Under 
selective conditions, the ROC curves for MAR versus mass showed excellent resolution of sensitive and resistant 
populations, with an average AUC of 0.85 (Fig. 4a,c). ROC curves using mass or MAR as single parameters had 
significant power to classify single cells, but the single parameters were less consistent between replicates and on 
average less accurate than using both parameters for classification (Fig. 4c, Supplementary Fig. 8). 
 
MAR predicts sensitivity of circulating leukemia cells  
Although GBM PDCLs and murine spleens provide access to an unlimited number of tumor cells, we wanted to 
measure MARs from small samples, simulating the limited tissue available with patient biopsies. To this end, we 
isolated tumor cells from the peripheral blood of mice by cheek bleed, which resulted in only 25 µL of total 
volume and does not compromise mouse survival. We performed these bleeds when circulating disease was as low 
as 4% of circulating mononuclear cells. This approach typically provided on the order of 103 total tumor cells for 
measurement following purification by flow sorting. In order to measure samples of low cell count and volume, we 
implemented a next-generation SMR array device that greatly simplifies fluidic handling, increasing throughput by 
20-fold and enables the use of low-volume samples 26. 
 
Single-cell MAR data was then collected on both cheek-bleed samples (~25 µL) and cardiac bleeds (~500 µL) 
exposed to either DMSO or 100 nM ponatinib for 14-20 hrs in vitro. Classification of single-cell drug response 
was similar using cheek-bleeds (AUC = 0.85) compared with measurements from splenocytes (AUC = 0.85) or 
cardiac bleeds (AUC = 0.80) (Fig. 4d, Supplementary Fig. 9). The ability of MAR measurements to assay drug 
sensitivity of single cells isolated from very small amounts of blood makes it feasible to longitudinally screen for 
phenotypic resistance within individual patients through iterative sampling. 
 
Patient cells reduce MAR when treated ex vivo or in vivo 
To define MAR assay compatibility with clinical samples, we ran two separate experiments using primary patient 
samples. First, we assayed ficolled peripheral blood samples from a patient with relapsed acute myeloid leukemia 
(AML). A sample obtained while the patient was not receiving treatment was composed largely of slightly positive 
MARs (Fig. 5a, Supplementary Fig. 10). After the patient had received 48 hrs of treatment with an experimental 
MDM2 inhibitor, a second peripheral blood sample was taken. This demonstrated a broader distribution of MARs 
compared to the pretreatment sample. Furthermore, a large population of cells with negative MARs of less than -1 
pg/hr appeared, indicating a shift in population MAR dynamics in vivo among the leukemia present in the 
peripheral blood (Fig. 5a, Supplementary Fig. 10). This shift towards negative MARs following treatment is 
consistent with our observations from ex vivo treatment of susceptible GBM patient-derived cell lines (Fig. 3) and 
murine primary cells (Fig. 4). 
 
Finally, we performed ex vivo treatment of a patient sample analogous to the approach applied to primary murine 
samples. Bone marrow leukemia cells from a patient presenting with newly diagnosed FLT3-mutated positive 
AML with MDS-related changes was treated in media with a range of therapeutics, including DMSO, 1 µM 
cytarabine (cytotoxic chemotherapy), 100 nM midostaurin (FLT3 and multikinase inhibitor), and an experimental 
MDM2 inhibitor (Fig. 5b). These cultures were incubated, and MARs were measured on three next- generation 
SMR array devices in parallel during 10-hour windows that centered on 20 and 44 hrs. Cells in midostaurin 
showed no significant change in their distribution of MAR as compared to a DMSO control, consistent with the 
limited activity of single-agent midostaurin in FLT3-mutated AML27. In comparison, cytarabine did result in a 
reduction in MAR that was highly significant (p=0.00015) at 48 hrs as compared to the control. Finally, cells 
treated with the experimental MDM2 inhibitor showed reduced MAR at 24 hrs, which rebounded by 48 hrs, 
potentially indicating a brief period of p53 target induction followed by the rapid induction of adaptive resistance. 
 
DISCUSSION 
Here we have presented a functional assay for assessing single cancer cell therapeutic sensitivity based on 
measurements of MAR and mass of individual cells.  We validated the predictive power of combining MAR and 
mass measurements by confirming susceptibility or resistance of genetically-defined cell lines, human GBM-
PDCLs, and primary murine ALLs in response to targeted therapeutics. Additionally, by measuring mass 
accumulation rates of single cells across a population and establishing a growth profile for different GBM-PDCLs 
and cell lines, we have shown for the heterogeneity of single-cell growth both within and across these populations. 
A substantial body of additional experiments will need to be performed to prove utility of MAR measurements for 
clinical decision making. However, our initial data with primary patient leukemia samples, treated either ex vivo or 
in vivo, showed responses that were consistent with our previously assayed in vivo models.  
 
MAR measurement within the SMR is not a terminal assay, as cells are kept viable throughout the measurement 
and thereby remain compatible with downstream analyses. Thus, a key advantage of MAR measurements is that 
cells can be studied downstream of the SMR using other single-cell assays, as we demonstrated by quantifying the 
tumorsphere-forming potential of GBM-PDCL cells after passage through the device (Supplementary Fig. 1). This 
ability will ultimately allow for correlations between single-cell changes in MAR, other functional outcomes and 
non-functional biomarkers (e.g. genetics, gene expression, chromatin modifications). Further studies are needed to 
assess the effects of passage through the SMR on aspects of tumor cell biology, including changes in the 
transcriptome, genome, and proteome. Previous studies have found that cellular and genomic properties of single 
cells can be measured using techniques such as RNA-sequencing and are well- preserved following exposure to 
microfluidic environments28. 
 
Recent studies have used other functional approaches to predict therapeutic sensitivity of individual cancers.For 
example, Crystal et al. applied standard proliferation-based assays to quantify therapeutic susceptibilities of bulk 
cultures of PDCLs 10. The results from their ex vivo screening predicted the response of in vivo xenografts to 
combination therapies. However, cell-to-cell heterogeneity is not captured by population approaches, and the utility 
of this strategy for clinical decision making is limited by the months of prolonged culture required for PDCL 
creation.  
 Montero et al. recently reported a functional approach called ‘dynamic BH3 profiling’, in which therapeutics are 
applied to cell lines or clinical tumor isolates, and then the percentage of cells that undergo mitochondrial outer 
membrane permeabilization (MOMP) is measured after introduction of a pro-apoptotic BH3 peptide29. Dynamic 
BH3 profiling robustly predicted which patients would respond to a given therapy across multiple cancer types. 
However, this approach requires cell permeabilization, which complicates the application of both downstream 
assays and phenotype validation, and does not clearly distinguish subsets of cells with phenotypic heterogeneity. 
 
MAR measurement addresses many of these limitations by assessing therapeutic susceptibility in single, live cells 
without the need for PDCL generation, but is subject to its own set of constraints. Most notably, in vitro culture is 
still necessary for a length of time adequate to elicit a growth response to applied therapeutics. In BaF3 cells this 
occurred within 2-4 hrs, but GBM cells required longer culture to appreciably change MAR in the presence of 
MDM2 inhibition. Thus, the MAR measurement can reduce, but does not completely eliminate, the time within in 
vitro culture. Additionally, the SMR currently requires cells to be in a single-cell suspension or small clumps for 
mass and MAR measurement. Future studies will explore the utility in solid tumor systems, where the extent of 
dissociation required may perturb cellular viability and/or response. MAR measurements also initially suffered 
from low throughput. However, single-cell mass and MAR can now be obtained with a throughput exceeding 60 
cells/hr/device without sacrificing precision26. 
 
Perhaps the most important shortcoming of our approach, and the vast majority of functional assays, is a potential 
bias towards assessing only cell intrinsic drug susceptibility. Microenvironmental interactions are known to 
influence in vivo drug response, but cellular ‘memory’ of these interactions may degrade during the course of ex 
vivo treatment9. There have been recent advancements in this arena involving implantable devices, but these 
approaches are currently only compatible with solid tumors, and require tumors of a minimum size that are easily 
accessible30. To address the role of microenvironmental interactions, future studies using MAR measurements 
should explore whether alternative culture conditions can help address the contribution of cell extrinsic factors 
under controlled conditions; e.g., tumor cells could be maintained in vitro in the presence of both drug and co-
culture with stromal and/or immune cells prior to measurement. Alternatively, patient drug response in situ could 
be monitored. For example, patient tumor cells could be analyzed with MAR measurements immediately before 
and hours to days following treatment to help inform pharmacokinetics and pharmacodynamics. In fact, we applied 
this approach to a patient with AML (Figure 5) to assess overall feasibility for clinical scenarios that could be 
explored in the future. 
 
Significant future work needs to be performed to define the utility of mass and MAR as biomarkers fortreatment 
response across disease types, in comparison to alternative functional assays, for drugs in combination, and across 
a wider range of drug mechanisms, where response may differ based on the mechanism of cell death. However, 
given the scarcity of functional assays with the necessary characteristics to merit widespread application, MAR 
measurements in the SMR hold potential as both a biological tool and a clinical platform. 
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FIGURE LEGENDS 
Figure 1: Mass accumulation rate (MAR) measurements characterize single-cell heterogeneity in growth across 
GBM-PDCLs and conventional cell lines. (a) Schematic of workflow. Single cells are weighed repeatedly over a 
15-minute interval by iterative passage through the SMR device. A linear fit is applied to those measurements 
and the resulting data is plotted as MAR versus buoyant cell mass. (b) MAR measurements over ~15 minutes for 
single cells from the BT145 GBM PDCL (top panel) and primary BCR-ABL ALL cells directly isolated from 
mice (bottom panel). Cells are dissociated (for BT145) or FACS purified (for ALL) and single cells are 
measured. The specific single-cell plots shown in the middle column are represented as red open-circles along 
with other single cells (black dots) plotted as a function of mass. (c) MAR versus mass distributions from 7 
GBM-PDCLs, 2 conventional hematopoietic cell lines (L1210 and BaF3-BCR-ABL) and one conventional 
GBM cell line (U87) for comparison. Each GBM-PDCL plot includes measurements from 3 successive passages 
in vitro (Supplementary Fig. 3), and each dot represents a single cell. From left to right, row by row, n = 84, 46, 
44, 51, 52, 61, 48, 46, 64, and 59 cells. 
 
Figure 2: Murine BaF3 lymphoblastoid cells rapidly reduce MAR upon exposure to active kinase inhibitors. (a) 
MAR versus cell mass of imatinib-sensitive BaF3-BCR-ABL or imatinib-resistant BaF3-BCR-ABL T315I cells 
exposed to 1 µM imatinib (imat.). (b, c) Same data as in (a) shown as MAR per mass (b) or mass box-plot (c), 
also including BaF3-BCR-ABL T315I cells treated with 100 nM ponatinib. Boxes represent the inter-quartile 
range and white squares the average of all measurements. p-values were calculated using the non-parametric 
Mann-Whitney U test, comparing treatment groups to DMSO for the same treatment duration. **** p<0.0001 in 
highlighted segments. Timepoints were taken on at least three biological replicate cultures on different days. 
From left to right, n = 46, 20, 48, 37, 36, 42, 15, 41, 27, 41, 41. 
 
Figure 3: MAR predicts sensitivity of human GBM-PDCLs to targeted therapy. (a) The expected response to 
RG7112 is outlined above each cell line, with the red ‘X’ indicating the drug’s ability to block the inhibition of 
p53 signaling by MDM2. The measured functional response of BT484, and 3731 (MDM2 amplified, TP53 wild-
type (WT)), BT159 (MDM2 WT, TP53 WT), and BT333 (MDM2 WT, TP53 mutated) PDCLs to DMSO or the 
MDM2 inhibitor RG7112 at a therapeutically relevant concentration of 1 μM over 36 hrs. IC50 data from 72 hr 
CellTiter-Glo measurements shown for reference. Complete data in Supplementary Fig. 5. Boxes represent the 
inter-quartile range and white squares the average of all cells. Gray circles show values for individual cells. p-
values were calculated using the non-parametric Mann-Whitney U test, comparing treatment groups to the 
DMSO control. ****p <0.0001 for highlighted segments. Timepoints were taken on biological replicate cultures 
on different days. From left to right, n = 59, 37, 25, 38, 37; 16, 18, 15, 15, 15; 15, 16, 14, 16, 15: 69, 32, 27, 37, 
38. (b) Same data as in (a), showing that the fraction of BT484 and 3731 cells with negative MARs increases 
upon exposure to RG7112 but remains unaffected in BT159 and BT333 cells. 
 
Figure 4: MAR distributions predict drug sensitivity of primary murine ALL cells to targeted therapy. (a) MAR 
per mass distributions of paired measurements from primary murine B-ALL cells dependent on BCR-ABL or 
BCR-ABL T315I and treated with 1 µM imatinib, 100 nM ponatinib, or DMSO. Measurements from individual 
mice are separated by a vertical dotted line. n indicates the number of cells for each measurement. AUC values 
for ROC curve of each paired dataset are listed below the x-axis. Boxes represent the inter-quartile range and 
white squares the average of all measurements. p-values were calculated using the non-parametric Mann-
Whitney U test, comparing treated cells to the DMSO control. (b) Representative MAR versus mass plot with 
overlay of an orthogonal vector (dotted line) designating the threshold resulting from LDA. (c) ROC curves of 
paired control and treatment data for each treatment replicate. Cells treated with therapy to which they are 
sensitive or resistant are shown with blue solid lines or red dotted lines, respectively. (d) MAR per mass 
distributions of paired measurements from primary murine B-ALL cells that are dependent on BCR-ABL. Cells 
isolated from the bloodstream of mice by either cardiac or cheek bleed and treated with 100 nM ponatinib or 
DMSO for the specified interval. p-values were calculated using the Mann-Whitney U test, comparing treated 
cells to the DMSO control. 
 
Figure 5: Patient samples treated in vivo or ex vivo show consistent reduction in MAR. (a) The fraction of cells 
with MAR of less than -1 pg/hr from pre-treatment patient sample (n = 86), and from sample obtained after the 
patient received 48 hrs of of treatment with an experimental MDM2 inhibitor (n = 95). MAR versus mass data 
for same sample set shown in Supplementary Figure 10. (b) Boxplots of MAR per mass of bone marrow 
leukemia cells treated ex vivo with either DMSO, 100 nM midostaurin, 1 µM cytarabine, or an experimental 
MDM2 inhibitor, and measured during 10 hour windows centered around 20 and 44 hrs. Boxes represent the 
inter-quartile range and white squares the average of all measurements. p-values were calculated using the non-
parametric Mann-Whitney U test, comparing treated cells to the DMSO control. From left to right, n = 137, 102, 
111, 78, 119, 103, 67, 48. 
MATERIALS AND METHODS 
Cell culture of conventional cell lines 
L1210, BaF3-BCR-ABL, and BaF3-BCR-ABL-T315I cells were maintained in suspension in RPMI-1640 
media (Invitrogen, Cat#11875-119), supplemented with 10% FBS (Sigma Aldrich, Cat#F4135), Penicillin-
Streptomycin (Invitrogen, Cat#15140-122 ), and kept in a 37 ˚C, 5% CO2, and humidified incubator. Cells 
were passaged every 2 days to 5x104 cells/mL, and used for SMR experiments between 24-36 hrs of growth at 
an approximate cell concentration of 2-4x105 cells/mL. L1210 cells were a gift from the Kirschner lab at 
Harvard, BaF3-BCR-ABL, and BaF3-BCR-ABL-T315I were created from the parental BaF3 cell line 
obtained from the RIKEN BioResource Center. No further cell line validation was performed. All cell lines 
tested negative for mycoplasma. 
 
For drug response experiments, cells in bulk were dosed for the specified interval with 0.1% DMSO, 1 µM 
imatinib (Santa Cruz Biotechnology, Cat#SC-202180), or 100 nM ponatinib (Selleckchem, Cat#AP24534). 
The cells were kept in drugged media during the measurements, and samples sizes were determined by 
practical limitations set by throughput. 
 
Creation and cell culture of GBM PDCLs 
GBM PDCLs were generated from patient tissue collected under an informed consent protocol (Dana Farber 
Harvard Cancer Center protocol #10-417) and two waived consent protocols (Dana Farber Harvard Cancer 
Center protocol #10-043 and Partner’s Human Research Center protocol #2002 P000995). All protocols 
mentioned have been approved by Dana Farber Harvard Cancer Center and Partner’s Human Research Center 
institutional review boards. Cells were harvested from excess tissue resection specimens through cycles of 
enzymatic (Neural tissue dissociation kit with papain, Miltenyi) and mechanical dissociation in a tissue grinder 
(gentleMACS dissociator, Miltenyi). Cells were grown as tumorspheres in NeuroCult NS-A proliferation 
media (Miltenyi) supplemented with 2 µg/ml Heparin, 20 ng/ml human epidermal growth factor (EGF), 10 
ng/ml human bFGF in ultra-low attachment coated flasks (Corning, Cat#3814), which were kept in a 37 ˚C, 
5% CO2, and humidified incubator. All PDCL’s tested negative for mycoplasma. 
 
Prior to loading in the SMR, the PDCLs were dissociated with Accutase (Sigma-Aldrich, Cat#A6964) at 37 ˚C 
for 7 minutes and plated as a single-cell population at 7-10x104 cells/ml. Tumorsphere forming assays were 
conducted by assessing the expansion of single-cells in a 96-well plate following 2 weeks of incubation, either 
isolated from the SMR, or as sorted by fluorescence activated cell sorting (FACS).  
 
For drug experiments, GBM-PDCLs were seeded into parallel cultures and treated with 1 µM of the MDM2 
inhibitor RG7112 (Selectchem), or DMSO. At each time point, one parallel culture was dissociated and 
immediately resuspended in drug media, and remaining parallel cultures were resuspended in fresh media with 
new drug. The dissociated cell suspensions were kept in drugged media during the measurements, and samples 
sizes were determined by practical limitations set by throughput. 
 
Transgenic mouse model of BCR-ABL B-ALL 
All animal experiments were performed with approval of the DFCI IACUC. A transgenic mouse model of BCR-
ABL B-ALL was generated by transplantation of lethally irradiated Ts1Rhr mice (B6.129S6-Dp(16Cbr1- 
ORF9)1Rhr/J; Jackson Laboratory, Bar Harbor, ME, USA; stock #005848) with syngeneic Hardy B cells 
transduced with an MSCV retrovirus coexpressing GFP and human BCR-ABL cDNA, as previously described18. 
For the present studies, 1x106 bulk splenocytes (P1 generation) were transplanted into lethally irradiated, wild- 
type, female, C57BL/6 mice at 6-8 weeks of age, which were followed daily for clinical signs of leukemia and 
sacrificed when moribund. Splenocytes or blood samples were harvested, subject to erythrocyte lysis (Qiagen, 
Cat#158904), and stained with an antibody targeting murine CD19 (Fisher Scientific, Cat#BDB551001). BCR- 
ABL B-ALL cells were isolated by sorting for CD19/GFP double-positive cells on a FACSAria II SORP 
fluorescence activated cell sorter (BD Biosciences). 
 
For drug response experiments, sorted mouse leukemia cells were seeded at a density of 5x105/mL and cultured 
at 37 ˚C in a humidified 5% CO2 incubator in RPMI (Gibco, Cat #11835055) supplemented with 10% FBS, 2 
mM L-glutamine (Gibco, Cat#25030164), 50 µM 2-mercaptoethanol (Sigma, Cat#M3148), 50 IU/ml-50 µg/mL 
penicillin-streptomycin (Fisher Scientific, Cat#ICN1670049), 10 ng/mL recombinant murine IL-3 (PeproTech, 
Cat#213-13), 10 ng/mL recombinant murine IL-7 (PeproTech, Cat#217-17), 10 ng/mL recombinant murine stem 
cell factor (PeproTech, Cat#250-03), and 10 ng/mL recombinant murine FLT3-ligand (PeproTech, Cat#250-
31L). Cells were kept in a 37 ˚C, 5% CO2, and humidified incubator. Replicate cultures were dosed for 10 hrs 
with 0.1% DMSO, 1 µM imatinib (Santa Cruz Biotechnology, Cat#SC-202180), or 100 nM ponatinib 
(Selleckchem, Cat#AP24534). The cells were kept in drugged media during the measurements, which took place 
between 10-20 hrs of drug exposure, and samples sizes were determined by practical limitations set by 
throughput and measurement window length. 
 
For in vivo confirmation of drug efficacy, female C57BL/6 mice were sublethally irradiated and transplanted with 
7.5x105 murine leukemia cells harboring human BCR-ABL cDNA, of which 95% were BCR-ABL wild type and 
5% harbored the T315I allele. Upon engraftment, as defined by the presence of circulating leukemia at a level of 
1-3% by peripheral blood flow cytometry, mice were treated with nilotinib 50 mg/kg/day via oral gavage (n=2 
mice). Nilotinib serves as a surrogate for imatinib, as both compounds have demonstrated activity against WT but 
not T315I BCR-ABL. Error bars represent standard deviation. Mice underwent serial BCR- ABL genotyping via 
the Sanger method to monitor the allelic frequency of BCR-ABL T315I. 
 
Patient sample procurement and processing 
Primary human leukemia specimens were collected from patients at the Dana-Farber Cancer Institute and 
Brigham and Women’s Hospital upon provision of informed consent under one or more tissue banking protocols 
(Dana-Farber/Harvard Cancer Center (DF/HCC) protocols #01-206 and #11-104). Each protocol has been 
approved by the DF/HCC institutional review board (IRB). Peripheral blood and bone marrow samples 
underwent Ficoll density gradient centrifugation to enrich for mononuclear cells, followed by immunomagnetic 
enrichment of leukemia cells using CD33 MicroBeads (Miltenyi, Cat#130-045-501) if concomitant clinical 
testing indicated that tumor purity was <80%. Leukemia cells were seeded at 0.5-1.0x106/mL in DMEM 
supplemented with 15% FBS, 2 mM L-glutamine, 50 µM 2-mercaptoethanol, 50 IU/ml-50 µg/mL penicillin- 
streptomycin, and human cytokines SCF (100 ng/mL, PeproTech #300-07), IL3 (10 ng/mL, PeproTech #200-03), 
IL6 ((20 ng/mL, PeproTech 200-06), TPO (10 ng/mL, PeproTech #300-18), and FLT3-Ligand (10 ng/mL, 
PeproTech 300-19), as adapted from published methods31. For measurements of in vivo response, aliquots of 
cultured cells were immediately measured in the presence of DMSO or sustained drug pressure with the 
experimental MDM2 inhibitor. In the case of ex vivo treatment, aliquots were treated with an experimental 
MDM2 inhibitor, cytarabine (1 µM), midostaurin (100 nM), or DMSO (1:1000) and were assessed using the 
SMR within 10-hour windows centered on 20 and 44 hours. 
 
CellTiter-Glo assay 
Cell viability in GBM neurospheres was assessed by quantification of ATP through chemiluminescence reading 
with CellTiter-Glo (Promega, Cat#G7570). GBM cells were plated as single cells at 2x103 cells/mL into wells of 
an ultra-low attachment coated 96-well plates (Corning, Cat#3474). In drug treatment experiments, viability was 
assessed at 72 hrs. All measurements were performed in triplicate according to manufacturer’s protocol. 
 
Measurement and operation of a suspended microchannel resonator (SMR) 
The design and operation of the SMR have been previously described13-15. In short, single cells in suspension are 
passed through the SMR resulting in a frequency shift that is proportional to cell buoyant mass. The SMR can 
resolve the instantaneous rate of mass accumulation for a single cell in 15 minutes provided that the cell is 
weighed approximately every 30 seconds. Mass calculated from frequency shift using a calibration factor derived 
from measurements of frequency shifts of polystyrene beads with a known mass (Thermo Scientific, 
Cat#4208A). Mass versus time data of a single cell is then linearly fitted. 
 
For measurement in the SMR, cells were suspended in their standard growth media with or without drug. For 
GBM-PDCLs poly-L-lysine/polyethylene-glycol (PLL-PEG) was added to the media at 10 µM to reduce cell- 
clumping and sticking to microchannel walls. Clumps of cells, visualized through a microscope during 
measurement, were excluded from measurement in the SMR. The system and cells were kept in culturing 
conditions (5% CO2, 37 ˚C) for all measurements as previously described
12. 
 
Flow cytometry 
All flow cytometry measurements were performed on a BD LSR II (BD Biosciences) using 4',6-diamidino-2- 
phenylindole (DAPI) (BioLegend, Cat#422801) and Annexin V (BioLegend, Cat#640907) 
 
 
Figure 1: Mass accumulation rate (MAR) measurements characterize single-cell heterogeneity in growth across 
GBM-PDCLs and conventional cell lines. (a) Schematic of workflow. Single cells are weighed repeatedly over 
a 15-minute interval by iterative passage through the SMR device. A linear fit is applied to those measurements 
and the resulting data is plotted as MAR versus buoyant cell mass. (b) MAR measurements over ~15 minutes 
for single cells from the BT145 GBM PDCL (top panel) and primary BCR-ABL ALL cells directly isolated 
from mice (bottom panel). Cells are dissociated (for BT145) or FACS purified (for ALL) and single cells are 
measured. The specific single-cell plots shown in the middle column are represented as red open-circles along 
with other single cells (black dots) plotted as a function of mass. (c) MAR versus mass distributions from 7 
GBM-PDCLs, 2 conventional hematopoietic cell lines (L1210 and BaF3-BCR-ABL) and one conventional 
GBM cell line (U87) for comparison. Each GBM-PDCL plot includes measurements from 3 successive 
passages in vitro (Supplementary Fig. 3), and each dot represents a single cell. From left to right, row by row, n 
= 84, 46, 44, 51, 52, 61, 48, 46, 64, and 59 cells. 
 
  
 
 
Figure 2: Murine BaF3 lymphoblastoid cells rapidly reduce MAR upon exposure to active kinase inhibitors. (a) 
MAR versus cell mass of imatinib-sensitive BaF3-BCR-ABL or imatinib-resistant BaF3-BCR-ABL T315I cells 
exposed to 1 µM imatinib (imat.). (b, c) Same data as in (a) shown as MAR per mass (b) or mass box-plot (c), 
also including BaF3-BCR-ABL T315I cells treated with 100 nM ponatinib. Boxes represent the inter-quartile 
range and white squares the average of all measurements. p-values were calculated using the non-parametric 
Mann-Whitney U test, comparing treatment groups to DMSO for the same treatment duration. **** p<0.0001 
in highlighted segments. Timepoints were taken on at least three biological replicate cultures on different days. 
From left to right, n = 46, 20, 48, 37, 36, 42, 15, 41, 27, 41, 41 
  
  
Figure 3: MAR predicts sensitivity of human GBM-PDCLs to targeted therapy. (a) The expected response to 
RG7112 is outlined above each cell line, with the red ‘X’ indicating the drug’s ability to block the inhibition of 
p53 signaling by MDM2. The measured functional response of BT484, and 3731 (MDM2 amplified, TP53 wild-
type (WT)), BT159 (MDM2 WT, TP53 WT), and BT333 (MDM2 WT, TP53 mutated) PDCLs to DMSO or the 
MDM2 inhibitor RG7112 at a therapeutically relevant concentration of 1 μM over 36 hrs. IC50 data from 72 hr 
CellTiter-Glo measurements shown for reference. Complete data in Supplementary Figure 5. Boxes represent 
the inter-quartile range and white squares the average of all cells. Gray circles show values for individual cells. 
p-values were calculated using the non-parametric Mann-Whitney U test, comparing treatment groups to the 
DMSO control. ****p <0.0001 for highlighted segments. Timepoints were taken on biological replicate cultures 
on different days. From left to right, n = 59, 37, 25, 38, 37; 16, 18, 15, 15, 15; 15, 16, 14, 16, 15: 69, 32, 27, 37, 
38. (b) Same data as in (a), showing that the fraction of BT484 and 3731 cells with negative MARs increases 
upon exposure to RG7112 but remains unaffected in BT159 and BT333 cells. 
  
 
 
Figure 4: MAR distributions predict drug sensitivity of primary murine ALL cells to targeted therapy. (a) MAR 
per mass distributions of paired measurements from primary murine B-ALL cells dependent on BCR-ABL or 
BCR-ABL T315I and treated with 1 µM imatinib, 100 nM ponatinib, or DMSO. Biological replicates from 
individual mice are separated by a vertical dotted line. n indicates the number of cells for each measurement. 
AUC values for ROC curve of each paired dataset are listed below the x-axis. Boxes represent the inter-quartile 
range and white squares the average of all measurements. p-values were calculated using the non-parametric 
Mann-Whitney U test, comparing treated cells to the DMSO control. (b) Representative MAR versus mass plot 
with overlay of an orthogonal vector (dotted line) designating the threshold resulting from LDA. (c) ROC 
curves of paired control and treatment data for each treatment replicate. Cells treated with therapy to which they 
are sensitive or resistant are shown with blue solid lines or red dotted lines, respectively. (d) MAR per mass 
distributions of paired measurements from primary murine B-ALL cells that are dependent on BCR-ABL. Cells 
isolated from the bloodstream of mice by either cardiac or cheek bleed and treated with 100 nM ponatinib or 
DMSO for the specified interval. p-values were calculated using the Mann-Whitney U test, comparing treated 
cells to the DMSO control. 
 
  
 
 
Figure 5: Patient samples treated in vivo or ex vivo show consistent reduction in MAR. (a) The fraction of cells 
with MAR of less than -1 pg/hr from pre-treatment patient sample (n = 86), and from sample obtained after the 
patient received 48 hrs of of treatment with an experimental MDM2 inhibitor (n = 95). MAR versus mass data 
for same sample set shown in Supplementary Figure 10. (b) Boxplots of MAR per mass of bone marrow 
leukemia cells treated ex vivo with either DMSO, 100 nM midostaurin, 1 µM cytarabine, or an experimental 
MDM2 inhibitor, and measured during 10 hour windows centered around 20 and 44 hrs. Boxes represent the 
inter-quartile range and white squares the average of all measurements. p-values were calculated using the non-
parametric Mann-Whitney U test, comparing treated cells to the DMSO control. From left to right, n = 137, 102, 
111, 78, 119, 103, 67, 48. 
 
